Greenwich LifeSciences, Inc. (GLSI) stock
GLSINasdaqPharmaceutical PreparationsFiscal year ends December 31
$20.58+1.88 (+10.05%)
Close on Nov 18, 2026Market cap $302.08MP/E –Yield –
Greenwich LifeSciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Greenwich LifeSciences's operating income for the twelve months ending Jun 30, 2026 was -$21.87M. For fiscal 2025 it was -$19.45M. The highest annual figure on record is -$1.86M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$19.45M | – |
| FY2024 | Dec 31, 2024 | -$17.64M | – |
| FY2023 | Dec 31, 2023 | -$9.33M | – |
| FY2022 | Dec 31, 2022 | -$8.04M | – |
| FY2021 | Dec 31, 2021 | -$4.60M | – |
| FY2020 | Dec 31, 2020 | -$1.86M | – |
| FY2019 | Dec 31, 2019 | -$3.43M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.02M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.73M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.94M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.17M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.77M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.77M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.71M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.73M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.66M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.54M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.84M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.50M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.75M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.24M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.89M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.38M | – |
| Q2 FY2022 | Jun 30, 2022 | -$773.31K | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.99M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.38M | – |
| Q3 FY2021 | Sep 30, 2021 | -$866.69K | – |
| Q2 FY2021 | Jun 30, 2021 | -$753.45K | – |
| Q1 FY2021 | Mar 31, 2021 | -$600.61K | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.15M | – |
| Q3 FY2020 | Sep 30, 2020 | -$256.87K | – |
| Q2 FY2020 | Jun 30, 2020 | -$210.43K | – |
| Q1 FY2020 | Mar 31, 2020 | -$244.64K | – |
| Q4 FY2019 | Dec 31, 2019 | -$336.54K | – |
| Q3 FY2019 | Sep 30, 2019 | -$336.01K | – |
See a number that looks wrong?